Merck Accelerates Scale Up of Lipids to Meet Covid-19 Demand Introduces new synthetic cholesterol product nine months ahead of scheduleOffers high purity, scalability, and consistent quality One of a few companies that produces lipids in quantities needed to meet demand for mRNA therapeutics, including Pfizer-B.
-
-
One of a few companies that produces lipids in quantities needed to meet demand for mRNA therapeutics, including Pfizer-BioNTech Covid-19 Vaccine
BURLINGTON, Mass., May 26, 2021 /PRNewswire/ To meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, MilliporeSigma has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule.
Filling of MilliporeSigma s new synthetic cholesterol product at the company s Darmstadt, Germany facility. This new product is more than 99 percent pure, offers high batch-to-batch consistency and is scalable under commercial GMP. Tapping into two decades experience of developing and manufacturing high-quality lipids, we designed a proprietary process to bring our new SAFC® synthetic cholesterol product to market nearly a year early, said Andrew Bulpin, head of Process Solutions at MilliporeSigma. With the introduction of our new SAFC® synthetic cholesterol product, we have
(Page 1) To meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, MilliporeSigma (Burlington, Mass.) has launched a new,
Merck Accelerates Scale Up of Lipids to Meet Covid-19 Demand iltempo.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iltempo.it Daily Mail and Mail on Sunday newspapers.
Merck Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies
- Response to unprecedented global demand of key technology
- Production capabilities anticipated to be operational by end of 2021
DARMSTADT, Germany, March 17, 2021 /PRNewswire/ Merck, a leading science and technology company, will add a single-use assembly production unit at its Life Science Center in Molsheim, France. With the € 25 million investment, the company is accelerating its European expansion plans for this key technology, which is used for the production of Covid-19 vaccines and other lifesaving therapies. Molsheim will be the first site in Europe where Merck manufactures the product. Further production sites are located in Danvers, Massachusetts, USA, and Wuxi, China.